These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

792 related articles for article (PubMed ID: 31070259)

  • 21. Diabetes, Plasma Glucose, and Incidence of Fatty Liver, Cirrhosis, and Liver Cancer: A Prospective Study of 0.5 Million People.
    Pang Y; Kartsonaki C; Turnbull I; Guo Y; Clarke R; Chen Y; Bragg F; Yang L; Bian Z; Millwood IY; Hao J; Han X; Zang Y; Chen J; Li L; Holmes MV; Chen Z
    Hepatology; 2018 Oct; 68(4):1308-1318. PubMed ID: 29734463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross-sectional analysis of 2011-2014 National Health and Nutrition Examination Survey.
    Wong RJ; Liu B; Bhuket T
    Aliment Pharmacol Ther; 2017 Nov; 46(10):974-980. PubMed ID: 28914448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation between non-alcoholic fatty liver with metabolic risk factors and brachial-ankle pulse wave velocity.
    Zhu WH; Fang LZ; Lu CR; Dai HL; Chen JH; Qiao QH; Chen LY
    World J Gastroenterol; 2015 Sep; 21(35):10192-9. PubMed ID: 26401084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of nonalcoholic fatty liver disease and liver cancer.
    Schulz PO; Ferreira FG; Nascimento Mde F; Vieira A; Ribeiro MA; David AI; Szutan LA
    World J Gastroenterol; 2015 Jan; 21(3):913-8. PubMed ID: 25624725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidemiology and disease burden of non-alcoholic steatohepatitis in greater China: a systematic review.
    Zou H; Ge Y; Lei Q; Ung COL; Ruan Z; Lai Y; Yao D; Hu H
    Hepatol Int; 2022 Feb; 16(1):27-37. PubMed ID: 35098442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data.
    Loomba R; Wong R; Fraysse J; Shreay S; Li S; Harrison S; Gordon SC
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1149-1159. PubMed ID: 32372515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis.
    Li J; Zou B; Yeo YH; Feng Y; Xie X; Lee DH; Fujii H; Wu Y; Kam LY; Ji F; Li X; Chien N; Wei M; Ogawa E; Zhao C; Wu X; Stave CD; Henry L; Barnett S; Takahashi H; Furusyo N; Eguchi Y; Hsu YC; Lee TY; Ren W; Qin C; Jun DW; Toyoda H; Wong VW; Cheung R; Zhu Q; Nguyen MH
    Lancet Gastroenterol Hepatol; 2019 May; 4(5):389-398. PubMed ID: 30902670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease.
    Bessissow T; Le NH; Rollet K; Afif W; Bitton A; Sebastiani G
    Inflamm Bowel Dis; 2016 Aug; 22(8):1937-44. PubMed ID: 27379445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps.
    Lonardo A; Nascimbeni F; Ballestri S; Fairweather D; Win S; Than TA; Abdelmalek MF; Suzuki A
    Hepatology; 2019 Oct; 70(4):1457-1469. PubMed ID: 30924946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.
    Bertot LC; Adams LA
    Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):179-187. PubMed ID: 30791782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection.
    Maurice JB; Patel A; Scott AJ; Patel K; Thursz M; Lemoine M
    AIDS; 2017 Jul; 31(11):1621-1632. PubMed ID: 28398960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease.
    Zeng J; Yang RX; Sun C; Pan Q; Zhang RN; Chen GY; Hu Y; Fan JG
    World J Gastroenterol; 2020 Apr; 26(15):1792-1804. PubMed ID: 32351294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.
    Ye Q; Zou B; Yeo YH; Li J; Huang DQ; Wu Y; Yang H; Liu C; Kam LY; Tan XXE; Chien N; Trinh S; Henry L; Stave CD; Hosaka T; Cheung RC; Nguyen MH
    Lancet Gastroenterol Hepatol; 2020 Aug; 5(8):739-752. PubMed ID: 32413340
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Moderate to severe, but not mild, nonalcoholic fatty liver disease associated with increased risk of gallstone disease.
    Lee YC; Wu JS; Yang YC; Chang CS; Lu FH; Chang CJ
    Scand J Gastroenterol; 2014 Aug; 49(8):1001-6. PubMed ID: 24989169
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population.
    Petta S; Di Marco V; Pipitone RM; Grimaudo S; Buscemi C; Craxì A; Buscemi S
    Liver Int; 2018 Nov; 38(11):2060-2068. PubMed ID: 29577560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epidemiology, disease burden and outcomes of cirrhosis in a large secondary care hospital in South Auckland, New Zealand.
    Hsiang JC; Bai WW; Raos Z; Stableforth W; Upton A; Selvaratnam S; Gane EJ; Gerred SJ
    Intern Med J; 2015 Feb; 45(2):160-9. PubMed ID: 25371019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
    Xu ZJ; Shi JP; Yu DR; Zhu LJ; Jia JD; Fan JG
    Adv Ther; 2016 Nov; 33(11):2069-2081. PubMed ID: 27743352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period.
    Pais R; Fartoux L; Goumard C; Scatton O; Wendum D; Rosmorduc O; Ratziu V
    Aliment Pharmacol Ther; 2017 Nov; 46(9):856-863. PubMed ID: 28857208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of fatty liver disease and the economy in China: A systematic review.
    Zhu JZ; Zhou QY; Wang YM; Dai YN; Zhu J; Yu CH; Li YM
    World J Gastroenterol; 2015 May; 21(18):5695-706. PubMed ID: 25987797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Burden of non-alcoholic fatty liver disease in Australia.
    Mahady SE; Adams LA
    J Gastroenterol Hepatol; 2018 Jun; 33 Suppl 1():1-11. PubMed ID: 29851153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.